Case Studies
Real-world success stories with Metis Scientific products
Reducing Depression Treatment Time by 40% with AI-Guided Neuromodulation
Challenge
The psychiatry department at University Hospital Vienna faced prolonged treatment times for major depressive disorder, with traditional trial-and-error approaches to antidepressant medication taking 8-12 weeks to show results. They needed a more precise, personalized approach to accelerate treatment response.
Solution
By integrating Synapse™ qEEG with Lumina™ AI analytics and Axion™ targeted neuromodulation, clinicians created personalized treatment protocols based on individual brain biomarkers. The system identified optimal stimulation parameters and predicted medication responsiveness.
Products Used:
"The integration of Synapse, Axion, and Lumina has transformed our approach to depression treatment. We're now able to provide truly personalized care with measurable, faster results."
— Dr. Maria Schmidt, Head of Psychiatry
Epilepsy Seizure Prediction Improves Patient Safety by 85%
Challenge
Epilepsy patients face constant uncertainty about when seizures will occur, limiting independence and causing anxiety. Traditional monitoring only captures events after they happen.
Solution
Charité implemented continuous monitoring with Synapse™ EEG and Lumina™ predictive AI, which learns individual seizure patterns and provides early warnings 5-15 minutes before onset.
Products Used:
"For our epilepsy patients, this technology is life-changing. The ability to predict seizures gives them back control and peace of mind."
— Dr. Anna Müller, Neurology Department
Early Alzheimer's Detection Enables 3-Year Intervention Window
Challenge
Traditional cognitive testing for Alzheimer's disease only detects changes after significant neurological damage has occurred. Researchers needed a way to identify at-risk individuals years before symptoms appear.
Solution
Using Synapse™ high-density EEG with Lumina™ AI biomarker analysis, researchers established a longitudinal study tracking 500 participants. Machine learning algorithms identified subtle brainwave pattern changes predictive of cognitive decline.
Products Used:
"This breakthrough in early detection is only possible because of the precision and reliability of the Synapse-Lumina platform. We're genuinely changing the trajectory of neurodegenerative disease."
— Prof. Dr. Thomas Weber, Principal Investigator
